印度尼西亚广阔的群岛提供丰富的海水资源,掌握盐生产潜力。盐,人类生活中的重要商品,通常含有氯化钠和Ca2+等杂质,Mg2+,SO42-,K+。药用盐是一个工业类别,坚持药典关于氯化钠水平和杂质含量的标准,确保印度尼西亚药物制剂的质量。先前的研究表明,重结晶,特别是蒸发结晶,通过增加NaCl含量来提高盐质量。可以引入化学沉淀剂如NaOH和Na2CO3以进一步提高盐纯度。本研究旨在确定从加工盐原料生产药用盐的最佳条件,考虑到结晶时间,搅拌速度,化学添加剂(NaOH和Na2CO3),和双结晶阶段。该方法从预处理开始,涉及盐在蒸馏水中溶解到饱和,根据指定的变量添加沉淀剂。通过过滤分离由沉淀剂(NaOH和Na2CO3)形成的沉淀物。滤液在103°C下进行蒸发结晶,在单结晶和双结晶之间变化。盐晶体被分离,干,并称重以计算产量。分析药用盐的含水量,NaCl,和杂质(Ca2+,Mg2+,SO42-,和K+)。药物盐生产的最佳条件是用过量20%的化学物质(NaOH和Na2CO3)进行双重结晶,100分钟的结晶时间,和600rpm的搅拌速度。这产生了99.87%的15%NaCl含量,Mg2+在0ppm,Ca2+在69.6ppm,SO42-在366ppm时,370ppm时的K+,含水量为0.166%。值得注意的是,药用盐生产过程不会产生浪费,作为副产物,如Mg(OH)2和CaCO3可以回收并具有商业价值。然而,必须重新评估原材料和技术,以解决市场的高成本和竞争力问题。
Indonesia\'s vast archipelago offers abundant seawater resources, holding the potential for
salt production.
Salt, a vital commodity in human life, typically contains sodium chloride and impurities like Ca2+, Mg2+, SO42-, and K+. Pharmaceutical salt is an industrial category adhering to pharmacopoeial standards regarding sodium chloride levels and impurity content, ensuring quality for drug preparations in Indonesia. Prior research indicates that recrystallisation, specifically evaporation crystallisation, enhances salt quality by increasing NaCl content. Chemical precipitating agents like NaOH and Na2CO3 can be introduced to improve
salt purity further. This
study aims to identify optimal conditions for pharmaceutical
salt production from processed
salt raw materials, considering crystallisation time, stirring speed, chemical additives (NaOH and Na2CO3), and double crystallisation stages. The method commences with pre-treatment, involving salt dissolution in distilled water to saturation, with the addition of precipitating agents as per designated variables. Precipitates formed from precipitating agents (NaOH and Na2CO3) are isolated through filtration. The filtrate undergoes evaporation crystallisation at 103 °C, varying between single and double crystallisation.
Salt crystals are separated, dried, and weighed to calculate yield. Pharmaceutical salt is analysed for water content, NaCl, and impurities (Ca2+, Mg2+, SO42-, and K+). The optimal conditions for pharmaceutical salt production were double crystallisation with a 20 % excess of chemicals (NaOH and Na2CO3), 100 min of crystallisation time, and a stirring speed of 600 rpm. This yielded a 15 % NaCl content of 99.87 %, Mg2+ at 0 ppm, Ca2+ at 69.6 ppm, SO42- at 366 ppm, K+ at 370 ppm, and water content at 0.166 %. Notably, the pharmaceutical salt production process generates no waste, as byproducts like Mg(OH)2 and CaCO3 can be recycled and hold commercial value. However, it is essential to re-evaluate raw materials and technologies to address the market\'s high cost and competitiveness issues.